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Abstract
Background—The key aims of this study were to identify sources of support for cancer registry 
activities, to quantify resource use and estimate costs to operate registries in low- and middle-
income countries (LMIC) at different stages of development across three continents.
Methods—Using the Centers for Disease Control and Prevention’s (CDC’s) International 
Registry Costing Tool (IntRegCosting Tool), cost and resource use data were collected from eight 
population-based cancer registries, including one in a low-income country (Uganda [Kampala)]), 
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two in lower to middle-income countries (Kenya [Nairobi] and India [Mumbai]), and five in an 
upper to middle-income country (Colombia [Pasto, Barranquilla, Bucaramanga, Manizales and 
Cali cancer registries]).
Results—Host institution contributions accounted for 30%–70% of total investment in cancer 
registry activities. Cancer registration involves substantial fixed cost and labor. Labor accounts for 
more than 50% of all expenditures across all registries. The cost per cancer case registered in low-
income and lower-middle-income countries ranged from US $3.77 to US $15.62 (United States 
dollars). In Colombia, an upper to middle-income country, the cost per case registered ranged from 
US $41.28 to US $113.39. Registries serving large populations (over 15 million inhabitants) had a 
lower cost per inhabitant (less than US $0.01 in Mumbai, India) than registries serving small 
populations (under 500,000 inhabitants) [US $0.22] in Pasto, Colombia.
Conclusion—This study estimates the total cost and resources used for cancer registration across 
several countries in the limited-resource setting, and provides cancer registration stakeholders and 
registries-with opportunities to identify cost savings and efficiency improvements. Our results 
suggest that cancer registration involve substantial fixed costs and labor, and that partnership with 
other institutions is critical for the operation and sustainability of cancer registries in limited 
resource settings. Although we included registries from a variety of limited-resource areas, 
information from eight registries in four countries may not be large enough to capture all the 
potential differences among the registries in limited-resource settings.
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1. Introduction
Health systems in the limited-resource setting currently face a rapidly increasing burden 
from noncommunicable diseases (NCDs), with at present, 80% percent of NCD-related 
deaths falling on these populations [1]. With an estimated 14.1 million new cancer cases, 8.2 
million deaths, and 32.5 million people living after cancer diagnosis (cancer survivors) 
worldwide in 2012, cancer is a leading cause of illness and early death [2]. More than 50% 
of the world’s cancer cases and 65% of cancer deaths occur in the limited-resource settings 
of the world, and more than 48% of cancer survivors live in these areas [3]. In the next two 
decades, new cancer cases are projected to increase by 70% worldwide—predominantly in 
limited-resource settings [4]. Cancer is responsible for one in three premature deaths from 
NCDs [5]. Cancer, along with diabetes, chronic respiratory disease, and cardiovascular 
disease were prioritized for action at the United Nations General Assembly on NCDs in 
2011 [6].
High-quality population-based cancer surveillance data are needed to: (1) describe cancer 
burden, patterns, and outcomes in order to (2) inform cancer prevention, detection and 
control activities; and (3) evaluate interventions on the basis of past and future trends so that 
optimal approaches to alleviate burden and suffering from cancer can be adopted. There are 
large inequalities in the existence, coverage, and quality of cancer surveillance systems 
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across the world, with limited information currently available in the limited-resource setting 
[7]. For example, the percentage of the population covered by cancer registries that meet the 
quality standards for inclusion in global statistics (Cancer Incidence in Five Continents, or 
CI5) ranges from nearly 100% in North America to less than 10% in Asia, Central America, 
and South America, and approximately 2% in Africa [8,9].
Only one in five countries in the limited-resource setting have the data needed to inform 
cancer control plans and reduce the burden from cancer [5]. To address this gap, the 
International Agency for Research on Cancer (IARC), a specialized agency of World Health 
Organization (WHO), has initiated the Global Initiative for Cancer Registry Development 
(GICR) [5] to establish regional resource centers to provide technical support and guidance 
for the development and improvement of population-based cancer registries around the 
world.
IARC has developed a framework for planning and implementing population-based cancer 
registries [9]. However, lack of accurate and reliable costing data is a major limitation to 
global, regional, and country efforts to plan, implement, and evaluate investments in cancer 
registration. The objectives of this study are therefore to (1) identify sources of funding and 
distribution of total resources by source; (2) determine the proportion of registry resources 
allocated to activities with variable and fixed costs, and the percentage of total resources 
allocated to labor; and (3) estimate operating cost per cancer case registered (cost per case) 
as well as the cost per inhabitant served (cost per inhabitant).
2. Material and methods
We collected data on the cost of registry operations (including funding and in-kind 
contributions) and resource utilization using a standardized data collection instrument, the 
US Centers for Disease Control and Prevention’s (CDC’s) International Registry Costing 
Tool (IntRegCosting Tool) [10]. The IntRegCosting Tool is based on a previously tested and 
validated instrument used to collect data from the CDC-supported state cancer registries in 
the US and extensively tailored for use in diverse types of registries [11]. The tool consists 
of 10 data collection modules that cover funding, cost and resource use, as well as registry 
characteristics. Cost data were collected for the following budget categories: labor, 
consultants, computers, travel, training, and other materials, software, and administrative or 
overhead. The distribution of registry resources by budget category is shown in Subramanian 
et al. [10]. Using a programmatic perspective, all costs and resource use relevant to program 
operations were collected. Therefore, all monetary and nonmonetary contributions to 
registry activities were available for a comprehensive assessment, representing the value of 
all resources required to operate a registry.
The IntRegCosting Tool included a data collection module to collect in-kind contributions, 
which included donated labor and non-labor resources. For example, the cost of donated 
labor was estimated using the average hourly wage for a person with similar qualifications 
obtained from national wage statistics. Additionally, we also estimated all the resources 
provided by the host institution whether through direct payments, such as staff salaries, or 
non-monetary contributions, such as office space or IT support.
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For this study, a convenience sample of eight regional population-based registries was 
selected from four countries that have on going or planned future collaboration with CDC on 
noncommunicable disease prevention and control efforts. Registries were selected to provide 
variation in geographic location, income category, case volume, and size of population 
covered. One year of data was collected from the registry in Kampala, Uganda (2014), four 
registries in the state of Maharashtra, India (Mumbai, Nagpur, Aurangabad and Pune in the 
fiscal year 2014–2015), and five registries in Colombia (Pasto, Barranquilla, Bucaramanga, 
Manizales, and Cali in fiscal year 2013). Two years of data were collected from Nairobi, 
Kenya (July 2012–June 2014). Registry staff collected cancer incidence data from medical 
facilities with which they had data sharing agreements or memoranda of understanding.
A user’s guide with standardized definitions and ongoing technical assistance were provided 
to registry staff and in-country consultants who assisted the registries. The in-country 
consultants helped ensure a clear understanding of terms among their country’s participating 
registries, including language translation in Colombia. Staff from each registry provided 
feedback on the definitions and classification of registry activities, and provided active input 
in developing the user’s guide. The research team provided technical assistance to registries 
at every stage of the data collection process via site visits, webinars, telephone calls, and e-
mail. Training and webinars were held with the research team, in-country consultants, and 
registry staff at regular intervals to ensure that all participants and collaborators had a clear 
understanding of the data elements and process for completing the IntRegCosting Tool. 
During the webinars, the research team provided examples of the cost data collection tool 
and shared high-level results from the economic analysis of US cancer registries [12] to 
show the value of the project and how the data can be used.
Costs were reported by registries using their local currency and converted to United States 
dollars (US $) using the official rate that corresponds with the year the costs were incurred 
(2013 for the Colombian registries and 2014 for the Indian registries, Nairobi and Kampala). 
Once the data were submitted, a series of data quality assessments were performed to ensure 
accuracy of the information. We assessed whether costs were allocated to all appropriate 
budget categories and whether all monetary contributions received from funding sources 
were assigned to specific registry activities. Registries had to allocate at least 90% of their 
costs to registry activities in order to meet the threshold for high-quality cost data. This 
threshold was determined based on prior work with registries funded by the CDC in the 
United States [10–12]. All registries met this standard. Additionally, we reviewed whether 
costs specifically related to labor were assigned to all core registry activities of data 
collection, analysis, and reporting for each annual period by reviewing the labor contribution 
by specific registry activity. When queries arose during the quality review process, the 
research team worked with registry staff and in-country consultants to clarify and correct 
data as needed before finalizing each data submission.
After data analysis, descriptive statistics were generated on registry characteristics, resources 
by budget category, and cost by registry activity. Registry activities were categorized into 
fixed-and variable-cost activities. Fixed-cost activities (those expected to not vary in cost in 
the short run as volume of cases change) included management, administration, training of 
registry staff, and IT support. Variable-cost activities (those expected to vary in cost as 
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volume of cases change) consisted of case ascertainment, data abstraction, data collection, 
data validation, and quality review, which were essential for registry operations, along with 
training of others by registry staff and research activities, which were not essential for 
registry operations. Detailed descriptions of all registry activities, along with the definitions, 
have been previously reported [10].
To compare cost of operations across registries, we calculated cost per cancer case registered 
(cost per case) and cost per inhabitant served (cost per inhabitant). Cost per case was 
calculated as total registry operating costs (including funding and in-kind contributions) 
divided by the number of incident cases diagnosed during a typical annual period. Cancer 
registries collect and process cases across multiple years in any given time period, and 
complete data for any case may only be available for a certain number of years; therefore, 
using data from a single year has been shown to be a good approximation for case load for 
most registries [11,13]. Cost per inhabitant was calculated as total registry operating costs 
for the period divided by the total population of the cancer registry coverage area. We report 
cost per case and cost per inhabitant in both US $ based on year of cost data collection and 
2011 purchasing power parity (PPP) [14]. PPP reflects a country’s ability to purchase a 
standardized set of goods and services, facilitating comparisons across countries. The PPP is 
the number of units of a country’s currency required to buy the same amounts of goods and 
services in the given nation as the US $ would buy in the US Thus, the PPP standardizes 
costs across countries using a common reference point: the US $. The US $, as the reference 
currency, is equal to unity. Reporting cost information in a common currency is a standard 
approach in health economics and one that is recommended by WHO [15].
3. Results
Table 1 presents the characteristics of the registries studied and clearly highlights the 
diversity of the registries included in this study. Registries from WHO regions of Africa, 
Asia, and the Americas are included and represent countries with low-, lower-middle-, and 
upper-middle-income countries. Four of the registries are based in a public university, two in 
a private university, one in a government research institute, and one in a private, non-
government organization. With the exception of the Nairobi registry, all registries have a 
continuous funding cycle. The average annual case volume among the registries ranges from 
726 incident cases diagnosed in Manizales, Colombia, to 19,485 in Mumbai, India. The size 
of the population covered as reported by the cancer registries ranges from 390,084 
(Manizales, Colombia) to 17,443,311 (Mumbai, India). The square kilometers covered 
ranges from 121 (Cali, Colombia) to 1914 (Kampala, Uganda). For most registries, cancer 
was not a reportable disease by national or regional legislation during the period of data 
collection, with the exceptions of Nairobi, Kenya and Pasto, Colombia. Registries 
considered to have high quality data are those that meet completeness, accuracy, and 
coverage criteria required for inclusion in the last volume of CI5 [16]. Most registries in our 
study had high quality data included in this global compendium of cancer incidence, with 
the exceptions of Nairobi and Barranquilla.
Sources of registry contributions include host institutions (such as a local university), 
national or local cancer or health organizations (such as the Colombian National Cancer 
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Institute), IARC, and other entities (supporting specialized studies). Fig. 1 presents the 
distribution of total resources by contribution source for each registry. Contributions from 
the host institutions (e.g. Kenya Medical Research Institute in Nairobi; Makerere University 
in Kampala; the Indian Cancer Society in Mumbai; and universities in Barranquilla, 
Bucaramanga, Cali, Manizales, and Pasto) provided valuable support for registry activities 
and accounted for 30% (Nairobi, Kenya) to 70% (Bucaramanga, Colombia) of registry 
operating resources. National or local organizations also provided substantial resources for 
registry operations in Colombia and Mumbai, ranging from 28% in Cali to 50% in 
Barranquilla. Most of these resources were provided to Colombian registries by the 
Colombian National Cancer Institute, and to Mumbai registry by India’s National Program 
of Cancer Registries. Support by international organizations, such as IARC or the 
International Network for Cancer Treatment and Research (INCTR), contributed to a large 
portion of the African countries’ resources, ranging from 42% in Kampala, Uganda to 70% 
in Nairobi, Kenya.
Cancer registries incurred significant fixed costs, accounting for nearly 20% (Bucaramanga, 
Colombia) to 45% (Manizales, Colombia) of total operating resources, as reported in Fig. 2. 
Cancer registry activities are labor intensive. Fig. 3 reports the percentage of total operating 
resources allocated to labor. Registries with a higher share of operating resources devoted to 
variable activities (Fig. 2) had a higher percentage of total resources allocated to labor (Fig. 
3). Table 2 shows the total number of staff full-time equivalents (FTEs) by cancer registry, 
the percentage of FTE by labor category, and the number of cancer cases per staff. Mumbai, 
India, including satellite registries, employs the largest number of staff (31 FTE), which is 
related to the large population covered. It has the largest number of cancer incident cases out 
of all the registries studied. Meanwhile, the Kampala Cancer Registry, which is located in 
the lowest income country in this study, had the smallest number of total staff (3 FTEs). The 
Manizales registry in Colombia also had a small number of total staff (3.6 FTEs), which is 
reflective of this registry having the smallest population within the registry coverage area 
and also the smallest number of cancer incident cases. On average, registrars and data 
collectors contributed to a little over half (58%) of the total staff for most registries, but there 
was a wide range by registry (28%–94%). Management and administrative staff ranged from 
6%–33% of total staff, while staff whose primary role was database management or research 
ranged from 0%–55%. Kampala, Uganda did not have any staff whose primary role was 
database management or research; however, did receive assistance with these activities 
through IARC consultants. Pasto, Colombia and Nairobi, Kenya also reported no staff with 
the primary role as research. Registries in low and lower middle income countries had a 
significantly higher number of cancer cases per staff than registries in Colombia, an upper 
middle income country. Pasto, Colombia had the smallest number of cancer incident cases 
per staff (116) while Kampala, Uganda had the largest number of cancer incident cases per 
staff (636).
Table 3 presents the cost per case and cost per inhabitant for each registry, both in US $ and 
PPP terms. Registries of low- and lower-middle-income countries had a significantly lower 
cost per case (ranging from 14.96 PPP [US $3.77] in Mumbai, India, to 39.62 PPP [US 
$15.62] in Nairobi, Kenya) compared with registries in upper-middle-income countries 
(ranging from 67.07 PPP [US $41.28] in Barranquilla, Colombia, to 184.25 PPP [US 
Tangka et al. Page 6
Cancer Epidemiol. Author manuscript; available in PMC 2018 March 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
$113.39] in Pasto, Colombia). Cost per inhabitant was related to size of population covered 
by the registry. Registries serving large populations (over 17 million inhabitants) had a lower 
cost per inhabitant (0.02 PPP [less than US $0.01] in Mumbai, India) than registries serving 
small populations (below 500,000 inhabitants) (0.36 PPP [US $0.22] in Pasto, Colombia). 
Cali, an established registry with significant resources devoted to special research projects, is 
an outlier among registries serving populations 2 million or higher, with a cost per inhabitant 
of 0.29 PPP (US $0.18).
4. Discussion
This is the first study to estimate the total cost and resources used for cancer registration 
across several countries in the limited-resource setting. Understanding such sources of 
funding, the allocation of resources, and the true cost of cancer registration serves multiple 
purposes: planning funding requirements, identifying resources required to improve and 
expand data collection activities, informing the establishment of new registries, and 
assessing efficiencies in data collection approaches. Of the limited number of studies that 
have been conducted on the economics of cancer registration, the majority are on CDC-
supported state cancer registries in the US [11–13,17–19]. Very few involve multiple 
countries [20,21]. Comparative analyses of the cost of registry operations across countries is 
challenging given national and regional differences in economic profiles, history, clinical 
and administrative background, and study approach [21]. A previous study used direct 
funding sources to estimate the cost per case for registries in the African Cancer Registry 
Network but did not include in-kind contributions, understating the true cost of operating a 
cancer registry [20]. Another previous study found comparable results for the Colombian 
registries, but used a more basic methodology that may have underestimated the costs for the 
lower-cost registries due to not accounting for all in-kind costs or funding from all sources 
[22]. To understand the total cost of cancer registration, it is essential to acknowledge the 
contributions made by all partners and to accurately assess the resources required for 
establishing, expanding, and enhancing cancer registry activities.
Partnerships are critical for the sustainability of cancer registries. The registries in this study 
did not operate as independent (single or stand-alone) entities; each one was part of an 
established institution, such as a university, hospital, medical research center, or nonprofit 
institution (e.g. a Cancer Society). Host institutions on average contributed 56% of the total 
value of resources needed to operate cancer registries, but there was wide range by registry 
(30%–70%). Host institutions provide significant in-kind contributions. For example, these 
institutions provide office space and utilities, some personnel (e.g., program directors and 
administrative assistants, whose salaries are fully or partially paid by the host institution 
because they assume other duties for the host institution), information technology support, 
transportation, and office supplies. Other partners also contribute to the success of cancer 
registration. For instance, IARC provides free software (CanReg5) [23] and technical 
assistance. One of the aims of the GICR, coordinated by IARC as an international 
partnership, is to help strengthen, expand, or establish new cancer registries in limited-
resource settings via the establishment of Regional Hubs. IARC also provides some financial 
support for registries in Africa. In Colombia, where population-based registries are 
institutionalized, the Colombian National Cancer Institute conducts annual reviews and 
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provides funding (in cash) and technical support for the operation of the registries based on 
findings from the reviews and site visits.
The distribution of resources by activities shows that substantial fixed costs are associated 
with registry activities. At least 20% of the total value of resources was associated with fixed 
costs (range 20%–45%). These fixed costs can relate to facilities and other infrastructure 
required for data processing and reporting, and some personnel salaries (e.g. registry 
director). Regardless of the case volume of a particular registry, fixed resources are needed. 
Therefore, sharing of fixed costs among small-volume registries or countries of a particular 
region, whenever possible, and centralization of certain processes, may help reduce the 
overall cost of cancer registration. For example, the Mumbai Cancer Registry and its three 
satellite registries in Pune, Nagpur, and Aurangabad, share registry operation costs. Data 
collectors at the satellites perform data abstraction, but Mumbai carries out all other core 
registration activities such as data analysis and quality assurance. Another example is the 
Barbados National Registry (BNR) for Chronic Noncommunicable Diseases (NCD) that 
registers both cancer and cardiovascular disease (CVD) cases. By using an integrated 
approach to NCD case registration, BRN shares fixed cost across registration of cancer and 
CVD cases. A study of CDC-supported state cancer registries in the US identified similar 
opportunities for low-volume registries to share resources to reduce cost of registry 
operations [12].
On average, labor accounted for about 68% (range 53%–93%) of the value of total resources 
of cancer registration, which reflects the labor-intensive nature of cancer registration. Labor 
is generally the highest cost component among all registries, including those in previous 
studies in the US and Europe [12,21]. The findings of this study highlight the potential for 
passive data reporting and automated processes that can increase efficiency through 
technology, reduce labor cost, and improve quality of the data. One potential approach can 
be to have, cancer registrars abstract data via (encrypted) electronic handheld devices, such 
as laptops or tablets instead of manually completing paper forms. Another potential 
approach is to modify the current data infrastructure that exists in the provider sites and 
hospitals to improve data collection efforts, including passive data reporting.
The underreporting of cancer incidence can add challenges to registries wishing to pursue 
more-passive data collection. It is relatively common for patients to take their medical files 
and reports home, which make them unavailable at provider sites and hospitals for data 
abstraction. Furthermore, clinicians do not routinely report cancer cases because cancer 
reporting is not mandated by law, as was the case in the majority of the registries. The 
underreporting of cancer incidence can be addressed by making cancer a reportable disease, 
by requiring a wide range of health care providers to report cases to cancer registries or by 
allowing registry staff access to their data. In some instances, additional financial and non-
financial resources may be needed to fulfill the reporting requirements. These mandates 
could reduce the workload and cost of cancer registry staff who find and abstract the cancer 
data, and decrease the time and resources needed by program managers to establish 
relationships and reporting agreements with data sources. Nevertheless, even in settings 
where cancer is a reportable disease, some level of active data collection will be needed.
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Cost per case and cost per inhabitant varied across registries. Cancer registries in low-
income countries had lower costs than registries in upper-middle-income countries. In a 
prior analysis in a high-income country, the main drivers of cost were case volume, size of 
area served, and quality of data available from providers [12]. The Mumbai registry, to 
highlight the impact of volume, collects data on the largest number of cancer cases among 
all the registries included in this study, and has the lowest cost per case. Other cost drivers 
could include cost of living, number of data sources, how records are stored, method of case 
finding (generally active rather than passive), method of data abstraction (largely using paper 
forms rather than electronic devices), requirements of annual renewal of agreements for data 
collection, size of the areas served by the registry [10], types of positions, and total number 
of staff per registry. For example, registries that rely on active case finding will need more 
resources related to travel and data collection labor if the registry covers a large geographic 
area. Registries in this study also varied in the data collection methods, with the African 
registries relying almost fully on paper-based methods, and Colombian registries reporting 
more of a mixture between paper and electronic-based methods. See Subramanian et al. for 
additional details on the internal and external factors that affect registry cost and data quality 
[10].
Overall, the cost of cancer registry operations per inhabitant is less than US $1, and is 
therefore a very small investment on a per-capita basis for the benefits of high quality 
information for cancer control that could be used toward reducing the enormous financial 
and nonfinancial burden from cancer [24,25].
Although this study provides the first comprehensive analysis of the total resources required 
to operate cancer registries in the limited-resource setting, it does have limitations. One of 
the potential limitations of the data analysis presented in this study is that the registries 
report data retrospectively; the potential for recall error makes the reliability of retrospective 
data uncertain. A second limitation is the geographic diversity of the registries. Although the 
cost data were converted from local currency to US $ and PPP to make comparison across 
countries easier and to account for regional variation, differences in costs between registries 
may persist. A third limitation is reporting information about cancer cases, which involves 
data collection for each case that may span several years. Thus, there may be a mismatch in 
aligning registry cost to the specific cases reported because of a lag in the reporting of 
cancer cases. Furthermore, registry funding from external sources can vary, so the 1-year 
estimates provided in this study may not be an accurate estimate of long-term trends. 
Additional rounds of data collection would allow for more stable estimates of the true cost 
of cancer registration. A fourth limitation in conducting this study is that the registries are 
part of large institutions, most of which have no formal budget and receive support from 
multiple sources, so it was difficult to account for total value of resources required to operate 
cancer registries. Thus, it is possible that these analyses underestimated the true costs of 
cancer registry operations. Zanetti et al. [21] observed a similar issue in conducting the 
economic evaluation of cancer registries in Europe. Fifth, although we verified that the 
quality of the economic data collected was high, we did not collect information on the 
quality of the cancer case data collected. We used inclusion in CI5 as our quality measure, 
and additional approaches to assess quality of the cancer case data may be needed. 
Therefore, the true cost of cancer registry operations may be understated if a registry is not 
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able to meet CI5 quality standards because of insufficient resources to produce high-quality 
data. Finally, even though we were able to include registries from a variety of limited-
resource areas, the overall sample size of the panel data of eight registries in four countries 
may not be large enough to capture all the potential differences among the registries in 
limited-resource settings.
5. Conclusions
This study provides information about the sources of support for cancer registry activities, 
the proportion of resources allocated to activities with fixed versus variable costs and to 
labor, and the total cost of operating cancer registries (including cost per case and cost per 
inhabitant). Such information is needed for efforts to establish, enhance, and expand cancer 
registration in limited-resource settings. This information can also provide cancer 
registration stakeholders and registries with opportunities to identify cost savings and 
efficiency improvements. Based on the findings from this study, registries have already 
begun assessing ways to improve their operations. For example, Kenya is using the cost data 
to plan its expansion of cancer registration to increase national coverage, and Colombian 
registries are assessing ways to increase operational efficiency. This study looked at a 
diverse range of registries from various countries and in various stages of development. 
Given the limited number of registries who participated, we need to collect cost data from an 
even larger number of cancer registries to derive the average cost of registering a cancer case 
in a region. This study has provided motivation for the current stage of the project, which is 
to expand use of the costing tool to a wider range of countries.
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Fig. 1. 
Distribution of Total Resources by Source.
NOTES: The costs were reported by cancer registry representatives for the following 
periods: Nairobi annual average July 2012–June 2014; Kampala 2014; Mumbai FY 2014–
2015; Colombian registries 2013.
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Fig. 2. 
Allocation of Resources to Fixed and Variable Costs.
NOTES: The costs were reported by cancer registry representatives for the following 
periods: Nairobi annual average July 2012–June 2014; Kampala 2014; Mumbai FY 2014–
2015; Colombian registries 2013.
Variable costs are inclusive of core registry activities, which are essential for registry 
operations, as well as other registry activities, such as enhanced analysis and research related 
tasks.
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Fig. 3. 
Percentage of Total Registry Costs Devoted to Labor by Cancer Registry.
NOTES: The costs were reported by cancer registry representatives for the following 
periods: Nairobi annual average July 2012–June 2014; Kampala 2014; Mumbai FY 2014–
2015; Colombian registries 2013.
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er
 m
id
dl
e
41
.2
8
67
.0
7
0.
05
0.
08
B
uc
ar
am
an
ga
U
pp
er
 m
id
dl
e
57
.5
1
93
.4
5
0.
11
0.
18
Ca
li
U
pp
er
 m
id
dl
e
81
.8
1
13
2.
94
0.
18
0.
29
M
an
iz
al
es
U
pp
er
 m
id
dl
e
67
.4
0
10
9.
52
0.
13
0.
20
Pa
st
o
U
pp
er
 m
id
dl
e
11
3.
39
18
4.
25
0.
22
0.
36
N
OT
ES
:
a T
he
 c
os
ts 
w
er
e 
re
po
rte
d 
by
 c
an
ce
r r
eg
ist
ry
 re
pr
es
en
ta
tiv
es
 fo
r t
he
 fo
llo
w
in
g 
pe
rio
ds
: N
ai
ro
bi
 a
nn
ua
l a
v
er
ag
e 
Ju
ly
 2
01
2–
Ju
ne
 2
01
4;
 K
am
pa
la
 2
01
4;
 M
um
ba
i F
Y
 2
01
4–
20
15
; C
ol
om
bi
an
 re
gi
str
ie
s 2
01
3.
b C
ur
re
nc
y 
co
nv
er
te
d 
fro
m
 lo
ca
l c
ur
re
nc
y 
to
 U
S 
$ f
or
 N
air
ob
i, K
am
pa
la,
 an
d M
um
ba
i d
ur
ing
 20
14
 an
d a
ll C
olo
mb
ian
 re
gi
str
ie
s d
ur
in
g 
20
13
.
c F
o
r 
in
ci
de
nt
 c
as
es
 d
ia
gn
os
ed
 n
um
be
rs
, w
e 
us
ed
 th
e 
fo
llo
w
in
g 
an
nu
al
 p
er
io
ds
: N
ai
ro
bi
 a
nn
ua
l a
v
er
ag
e;
 K
am
pa
la
 2
01
2 
ca
se
s; 
M
um
ba
i 2
01
2 
ca
se
s; 
Co
lo
m
bi
an
 re
gi
str
ie
s 2
01
0 
ca
se
s.
d P
ur
ch
as
in
g 
po
w
er
 p
ar
ity
 (P
PP
), 2
01
1 I
nte
rna
tio
na
l C
om
pa
ris
on
 Pr
og
ram
, W
o
rld
 B
an
k.
e C
os
t p
er
 in
ha
bi
ta
nt
 is
 d
ef
in
ed
 a
s t
he
 to
ta
l c
an
ce
r r
eg
ist
ry
 c
os
ts 
fo
r t
he
 a
nn
ua
l p
er
io
d 
di
v
id
ed
 b
y 
th
e 
to
ta
l p
op
ul
at
io
n 
of
 th
e 
ca
nc
er
 re
gi
str
y 
co
v
er
ag
e 
ar
ea
.
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